US-based biopharmaceutical company AbbVie has acquired Celsius Therapeutics, a biotechnology company developing therapies for inflammatory diseases, for $250m. The strategic move expands AbbVie’s footprint in the treatment of inflammatory diseases, adding a potentially transformative...

  Belharra Therapeutics has announced that it has entered a strategic partnership with global powerhouse Sanofi to spur the development of small molecule therapies for immunological diseases. Under the terms of the agreement, the San Diego, California-based next-generation...

  ANI Pharmaceuticals and Alimera Sciences had announced they have signed a definitive agreement pursuant to which ANI will acquire Alimera for $5.50 per share in cash at closing and one non-tradable contingent value right (CVR) representing the right to receive up to $0.50 per...

EQT is pleased to announce that the EQT Healthcare Growth Strategy and the EQT Growth Fund have agreed to acquire a majority stake in CluePoints  with meaningful reinvestment from the management team and existing shareholders Summit Partners and Clinimetrics SA, which was also a...